Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2604-2614

  Innocenti, Federico ^a   Kroetz, Deanna L ^a   Schuetz, Erin ^a   Dolan, M Eileen ^a   Ramírez, Jacqueline ^a   Relling, Mary ^a   Chen, Peixian ^a   Das, Soma ^a   Rosner, Gary L ^a   Ratain, Mark J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; BILIRUBIN; BREAST CANCER RESISTANCE PROTEIN; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HNF1A PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

ADVANCED CANCER; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; DRUG ELIMINATION; DRUG MECHANISM; ENZYME POLYMORPHISM; EUROPEAN AMERICAN; FEMALE; GENE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UGT1A1 GENE; ADULT; AGED; BIOTRANSFORMATION; BLOOD; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PHENOTYPE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; BIOTRANSFORMATION; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIVARIATE ANALYSIS; NEUTROPENIA; ORGANIC ANION TRANSPORTERS; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 66849111193     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6300     Document Type: Article

References (41)

1. Kim TW, Innocenti F: Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 29:265-270, 2007
2. Hoskins JM, Goldberg RM, Qu P, et al: UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst 99:1290-1295, 2007
3. Iyer L, King CD, Whitington PF, et al: Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854, 1998
4. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95:8170-8174, 1998
5. Innocenti F, Vokes EE, Ratain MJ: Irinogenetics: What is the right star? J Clin Oncol 24:2221-2224, 2006
6. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388, 2004
7. Innocenti F, Ratain MJ: Pharmacogenetics of irinotecan: Clinical perspectives on the utility of genotyping. Pharmacogenomics 7:1211-1221, 2006
8. O'Dwyer PJ, Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: Practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534-4538, 2006
9. US Food and Drug Administration: FDA clears genetic test that advances personalized medicine test helps determine safety of drug therapy. http://www.fda.gov/bbs/topics/NEWS/2005/NEW01220.html
10. Zhang W, Liu W, Innocenti F, et al: Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms. PLoS ONE 2:e396, 2007
11. Strassburg CP, Oldhafer K, Manns MP, et al: Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-220, 1997
12. Han JY, Lim HS, Shin ES, et al: Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59:69-75, 2008
13. Xiang X, Jada SR, Li HH, et al: Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics 16:683-691, 2006
14. Han JY, Lim HS, Yoo YK, et al: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110:138-147, 2007
15. de Jong FA, Scott-Horton TJ, Kroetz DL, et al: Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81:42-49, 2007
16. Mathijssen RH, Marsh S, Karlsson MO, et al: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253, 2003
17. Rosner G, Panetta J, Innocenti F, et al: Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther 84:393-402, 2008
18. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002
19. Innocenti F, Grimsley C, Das S, et al: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725-733, 2002
20. Côté JF, Kirzin S, Kramar A, et al: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13:3269-3275, 2007
21. Leabman MK, Huang CC, DeYoung J, et al: Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A 100:5896-5901, 2003
22. Conrad S, Kauffmann HM, Ito K, et al: Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46:656-663, 2001
23. Conrad S, Kauffmann HM, Ito K, et al: A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321-330, 2002
24. Leslie EM, Létourneau IJ, Deeley RG, et al: Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42:5214-5224, 2003
25. Létourneau IJ, Deeley RG, Cole SP: Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 15:647-657, 2005
26. Oselin K, Mrozikiewicz PM, Gaikovitch E, et al: Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: Detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59:347-350, 2003
27. Moriya Y, Nakamura T, Horinouchi M: Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25:1356-1359, 2002
28. Haenisch S, May K, Wegner D, et al: Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 18:357-365, 2008
29. Haenisch S, Zimmermann U, Dazert E, et al: Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7:56-65, 2007
30. Pasanen MK, Neuvonen M, Neuvonen PJ, et al: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873-879, 2006
31. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80:356-366, 2006
32. Link E, Parish S, Armitage J, et al: SLCO1B1 variants and statin-induced myopathy: A genome-wide study. N Engl J Med 359:789-799, 2008
33. Kim SR, Saito Y, Sai K, et al: Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Drug Metab Pharmacokinet 22:456-461, 2007
34. Roth AD, Yan P, Dietrich D, et al: Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5-fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3-EORTC 40993-SAKK 60/00 trial comparing IRI/5-FU/folinic acid (FA) to 5-FU/FA in stage II-III colon cancer (COC) patients. J Clin Oncol 26:187s, 2008 (suppl; abstr 4036)
35. de Jongh FE, Verweij J, Loos WJ, et al: Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733-3739, 2001
36. Mathijssen RH, Verweij J, de Jonge MJ, et al: Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 20:81-87, 2002
37. de Jong FA, Mathijssen RH, Xie R, et al: Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 10:4068-4071, 2004
38. Ramchandani RP, Wang Y, Booth BP, et al: The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47:78-86, 2007
39. Meyerhardt JA, Kwok A, Ratain MJ, et al: Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 22: 1439-1446, 2004
40. Freyer G, Rougier P, Bugat R, et al: Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure: CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 83:431-437, 2000
41. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: Current status and future challenges. Pharmacogenomics J 7:99-111, 2007